UK/Canada Deal Lets Drug Agencies Avoid Brexit-Related Trade Disruption
An interim trade deal between the UK and Canada means that the regulators in these countries will carry on accepting each other’s batch testing and GMP certificates.
You may also be interested in...
There may not be a great deal in the new UK-EU trade and cooperation deal for the life sciences industry but a new working group could act as the forum for constructive discussions on regulatory cooperation.
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New medicines under evaluation at the European Medicines Agency.